Targeted a-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle–emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective treatment of local lesions and micrometastases. However, profound assessment of the immunomodulatory effect of α-TRT is lacking in literature.
ERTVELDT Thomas;
KRASNIQI Ahmet;
CEUPPENS Hannelore;
PUTTEMANS Janik;
DEKEMPENEER Yana;
DE JONGHE Kevin;
DE MEY Wout;
LECOCQ Quentin;
DE VLAEMINCK Yannick;
AWAD Robert Maximilian;
GOYVAERTS Cleo;
DE VEIRMAN Kim;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
KEYAERTS Marleen;
DEVOOGDT Nick;
D'HUYVETTER Matthias;
BRECKPOT Karine;
2023-10-11
SOC NUCLEAR MEDICINE INC
JRC134534
0161-5505 (online),
https://jnm.snmjournals.org/content/64/5/751,
https://publications.jrc.ec.europa.eu/repository/handle/JRC134534,
10.2967/jnumed.122.264752 (online),
Additional supporting files
| File name | Description | File type | |
|---|
